QR-Code

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

Abstract Background Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mCRPC presents with oligoprogressive disease, with a limited number of pr...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Charlien Berghen, Steven Joniau, Kato Rans, Gaëtan Devos, Kenneth Poels, Koen Slabbaert, Herlinde Dumez, Maarten Albersen, Karolien Goffin, Karin Haustermans, Gert De Meerleer
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2020-05-01
Schriftenreihe:BMC Cancer
Schlagworte:
Oligoprogression
Prostate cancer
Stereotactic body radiotherapy
Metastasectomy
Lymph node dissection
Next-line systemic treatment
Online-Zugang:http://link.springer.com/article/10.1186/s12885-020-06853-x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge